Acne vulgaris Epidemiology

• In 2023, there were approximately 29,433 thousand diagnosed prevalent cases of acne vulgaris in the 7MM, these cases are further expected to increase during the forecast period (2024–2034). 
• Factors contributing to the rise of diagnosed prevalent cases of acne vulgaris include hormonal changes, dietary influences, genetic predisposition, and environmental factors such as pollution.
• The total diagnosed prevalence of acne vulgaris in the 7MM is expected to increase at a CAGR of 0.4% owing to changes in lifestyles, diet and escalated changes in the hormonal levels. 
• The Age-specific prevalent cases of acne vulgaris are divided into the following groups: 15-19 years, 20-29 years, 30-39 years, 40-49 years, and 50 years and older. In the United States, a higher number of cases were observed in the age group 15-19 years compared to others, comprising around 5,853 thousand cases in 2023.
• Among EU4 and the UK, Germany had the highest diagnosed prevalent population of acne vulgaris, with 3,486,784 cases, followed by France and Italy in 2023.
• As per DelveInsight’s estimates, Japan accounted for nearly 10% of the Total Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM in 2023.

DelveInsight’s “Acne Vulgaris – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Acne Vulgaris, historical and forecasted epidemiology of Acne Vulgaris in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Acne Vulgaris Disease Understanding 

Acne Vulgaris Overview

Acne vulgaris is a chronic inflammatory dermatological condition characterized by pimples, blackheads, and whiteheads on the skin, primarily affecting pilosebaceous units across various age groups, with adolescents being the most commonly affected demographic. The severity of acne can be classified into mild, moderate, and severe based on the presence of non-inflammatory and inflammatory lesions, erythema, and scarring. The pathogenesis involves a multifactorial interplay of hormonal influences, sebum production, follicular hyperkeratinization, bacterial proliferation, and inflammation, exacerbated by genetic predisposition, medications, and environmental factors. Key symptoms include comedones, inflammatory lesions, and scarring. The management of acne is challenging due to various risk factors, emphasizing the need for comprehensive understanding and targeted interventions.

Acne Vulgaris Diagnosis

Diagnosis of acne vulgaris typically involves a thorough clinical examination of the skin to assess the type, severity, and distribution of lesions. In some instances, additional diagnostic procedures are employed to rule out other skin conditions or determine bacterial involvement. These procedures include skin biopsies and microbial cultures. Furthermore, additional tests such as microbial testing, hormonal evaluations, and liver function tests may be conducted in specific cases to provide a comprehensive understanding of the condition.

Further details related to diagnosis are provided in the report…

Acne Vulgaris Epidemiology

For the purpose of designing the patient-based model for the Acne Vulgaris epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Prevalent Cases of Acne Vulgaris, Diagnosed Prevalent Cases of Acne Vulgaris, Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris, Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris, and Age-specific Diagnosed Prevalent Cases of Acne Vulgaris in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2021 to 2034. 

• In 2023, an estimated ~140,217 thousand prevalent cases of Acne Vulgaris occurred across the 7MM, with approximately 69,500 thousand cases attributed to the US alone. These numbers are expected to increase steadily throughout the forecast period.
• The categorization based on gender, showed that diagnosed prevalent cases in females were higher than in males in the 7MM. The female-diagnosed prevalent cases accounted for 63% of the total cases in the 7MM.
• The prevalent cases of acne vulgaris were sub-segmented further based on the severity of the acne as mild, moderate, and severe. In 2023, the highest diagnosed prevalent cases of acne vulgaris were reported as moderate (45%), whereas there were least cases in the severe (10%) segment in the 7MM.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence. 

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia; Wake Forest University School of Medicine, North Carolina; Department of Dermatology and Venereology, University Clinic Hamburg-Eppendorf, Hamburg, Germany; La Roche-Posay Pharmaceutical Laboratory, France; and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Acne Vulgaris, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Acne Vulgaris Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Total Prevalent Cases of Acne Vulgaris
• Total Diagnosed Prevalent Cases of Acne Vulgaris
• Severity-specific Diagnosed Prevalent Cases of Acne Vulgaris
• Gender-specific Diagnosed Prevalent Cases of Acne Vulgaris
• Age-specific Diagnosed Prevalent Cases of Acne Vulgaris

Acne Vulgaris Report Key Strengths

• 11 years Forecast
• The 7MM Coverage 
• Acne Vulgaris Epidemiology Segmentation 

Acne Vulgaris Report Assessment

• Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Acne Vulgaris? What will be the growth opportunities across the 7MM concerning the patient population of Acne Vulgaris?
• What is the historical and forecasted Acne Vulgaris patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why is the diagnosed prevalent cases of Acne Vulgaris in Japan lower than the US?
• Which country has a high patient share for Acne Vulgaris?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the Acne Vulgaris prevalence cases in varying geographies over the coming years.
• A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Acne Vulgaris, along with diagnosed prevalence of Acne Vulgaris Based on severity of airflow limitation and diagnosed prevalence of Acne Vulgaris based on symptoms and exacerbation history.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.